La Roche-Posay and L’Oreal Sensitive Skin Research

Written by on March 30, 2012 in research with 0 Comments

Thought that the following Poster Session from the recent 2012 AAD Annual Meeting in San Diego was encouraging because we really do want to see new products being developed specifically for people with sensitive skin.

La Roche Posay is one of the skincare brands owned by L’Oreal. La Roche Posay may be known to rosacea sufferers through the actually little-known Rosaliac UV Fortifying Anti-Redness Moisturizer.

Poster reference number 4680

Clinical usefulness of a product developed for sensitive and allergy prone skin

American Academy of Dermatology 70th Annual Meeting, March 16–20, 2012, San Diego, California. Poster Abstracts, Supplement to JAAD, April 2012, Volume 66, Number 4.

Sophie Seite, PhD, La Roche-Posay Dermatological Laboratories, Asnieres, France; Andre Rougier, PhD, La Roche-Posay Dermatological Laboratories, Asnieres, France; Florence Benech, PharmD, L’Oreal Research & Innovation, Chevilly Larue, France; Muriel Bayer-Vanmoen, PhD, L’Oreal Research & Innovation, Chevilly Larue, France; Sophie Veyrat, PharmD, L’Oreal Research & Innovation, Chevilly Larue, France

Sensitive skin as described by the patients is an extremely polymorphous symptomatology with subjective complaints of discomfort (burning, stinging, and itching) with or without visible signs (erythema and desquamation) up to allergy.

The present study evaluates the benefits of a specially developed product for patients with sensitive or pathologic skin.

Having taken the battery of safety testing including repeated insult patch test, use tests on patients with sensitive skin or with a medical history of sensitivity to at least 2 allergens of the European standard series, the product was evaluated first in 41 women with sensitive skin (positive to a lactic acid stinging test) then in 102 women with atopy prone (n = 49) or with erythrocouperosis/rosacea prone (n = 53) skin.

They all applied the product twice daily for 4 weeks.

Evaluation at baseline and after 4 weeks included stinging test, Sensiscore questionnaire, clinical grading with a 9-point scale and self-evaluation questionnaire of skin reactivity with a 5-point scale.

In the second test, clinical grading of functional signs and of physical signs using a 4-point scale and self evaluation of reactivity to exogenous factors via a 10-cm visual analog scale were performed at the same times.

A good tolerance was noticed together with a significant reduction of physical and functional symptoms of skin reactivity at the end of the 4-week treatment as well as a reduction of skin reactivity in both studies.

Commercial Support: La Roche-Posay Dermatological Laboratories Asnieres France.

Related Articles

Read more about: research

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

Leave your comment here


Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.